Logo

Ciphergen, BioMerieux Partner for Biomarker Discovery

Jun 30, 2003

NEW YORK, June 30 - Ciphergen Biosystems and diagnostics firm BioMerieux have entered a collaboration using Ciphergen's ProteinChip technology to discover biomarkers that may improve the diagnosis and management of colon cancer, Ciphergen said today.

 

Ciphergen will install its technology platform at BioMerieux's Marcy-l'Etoile, France, site and the company's Biomarker Discovery Center team will collaborate with BioMerieux's research team.

 

Financial terms of the agreement were not disclosed.

Breaking News
The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.